Colorectal Cancer Therapeutics Market Size & Share, by Therapy (Targeted Therapy, Immunotherapy, Chemotherapy, Radiation Therapy, Embolization, Surgery); Cancer Type (Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors); Application (Hospitals, Clinics, Research institutions); End-user (Hospitals, Ambulatory Surgical Centers, Clinics, Diagnostic Imaging Centers) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

  • Report ID: 436
  • Published Date: Feb 13, 2023
  • Report Format: PDF, PPT

Companies Dominating the Colorectal Cancer Therapeutics Landscape

top-features-companies
    • Novartis AG
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Pfizer Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • Bristol-Myers Squibb Company
    • Bayer AG
    • Amgen Inc.
    • Genentech, Inc.
    • Teva Pharmaceuticals Industries Ltd.
    • Ipsen Biopharmaceuticals, Inc.

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Ipsen Biopharmaceuticals, Inc. completed the acquisition of Epizyme Inc. and expanded its oncology portfolio.
  • Novartis AG announced the promising clinical data for its investigational KRASG12C inhibitor JDQ443, an investigational selective, covalent, and orally bioavailable inhibitor at the annual meeting of the American Association for Cancer Research (AACR)


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 436
  • Published Date: Feb 13, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Worldwide increasing prevalence of cancer, emerging novel therapies for cancer treatment, significant research on novel drugs, and global surge in geriatric population are some major factors driving the growth of the market.

The market is anticipated to attain a CAGR of 10% over the forecast period, i.e., 2023-2033.

High cost of cancer drugs, concern for adverse effect associated with the treatment, and long term procedures of cancer treatments are estimated to hamper the market growth.

The market in North America is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are Novartis AG, Pfizer Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Bayer AG, Amgen Inc., and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by therapy, cancer type, application, end-user, and by region.

The targeted therapy segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying